Plant Name: Actaea dahurica
Taxonomic Information:
Plant ID: NPO15373
Plant Latin Name: Actaea dahurica
Taxonomy Genus: Actaea
Taxonomy Family: Ranunculaceae
Plant External Links:
NCBI TaxonomyDB:
64029
Plant-of-the-World-Online:
n.a.
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| TSHR; | |
| FFAR1; | |
| PTPN1; | |
| GLA; TDP1; HSD17B10; ALOX15; ALDH1A1; | |
| ACHE; | |
| MAPK1; | |
| CA2; CA12; CA1; CA9; CA7; CA3; CA14; CA5B; CA5A; CA4; CA6; | |
| PPARA; PPARD; | |
| CASP1; CASP7; | |
| MMP9; MMP1; MMP2; | |
| TLR2; | |
| HIF1A; TP53; NFKB1; | |
| SLC22A8; SLC22A6; | |
| LMNA; FABP3; FABP5; FABP2; FABP4; | |
| XDH; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cysteine protease | CASP1 | Caspase-1 | P29466 | CHEMBL4801 |
| Cysteine protease | CASP7 | Caspase-7 | P55210 | CHEMBL3468 |
| Cytochrome P450 family 2 | CYP2A6 | Cytochrome P450 2A6 | P11509 | CHEMBL5282 |
| Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
| Enzyme_unclassified | GLA | Alpha-galactosidase A | P06280 | CHEMBL2524 |
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
| Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
| Enzyme_unclassified | ALDH1A1 | Aldehyde dehydrogenase 1A1 | P00352 | CHEMBL3577 |
| Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA1 | Carbonic anhydrase I | P00915 | CHEMBL261 |
| Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA3 | Carbonic anhydrase III | P07451 | CHEMBL2885 |
| Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
| Lyase | CA5B | Carbonic anhydrase VB | Q9Y2D0 | CHEMBL3969 |
| Lyase | CA5A | Carbonic anhydrase VA | P35218 | CHEMBL4789 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Lyase | CA6 | Carbonic anhydrase VI | P23280 | CHEMBL3025 |
| Metallo protease | MMP9 | Matrix metalloproteinase 9 | P14780 | CHEMBL321 |
| Metallo protease | MMP1 | Matrix metalloproteinase-1 | P03956 | CHEMBL332 |
| Metallo protease | MMP2 | Matrix metalloproteinase-2 | P08253 | CHEMBL333 |
| Nuclear hormone receptor subfamily 1 group C | PPARA | Peroxisome proliferator-activated receptor alpha | Q07869 | CHEMBL239 |
| Nuclear hormone receptor subfamily 1 group C | PPARD | Peroxisome proliferator-activated receptor delta | Q03181 | CHEMBL3979 |
| Oxidoreductase | XDH | Xanthine dehydrogenase | P47989 | CHEMBL1929 |
| Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
| Protein Kinase | MAPK1 | MAP kinase ERK2 | P28482 | CHEMBL4040 |
| Protein Phosphatase | PTPN1 | Protein-tyrosine phosphatase 1B | P18031 | CHEMBL335 |
| SLC superfamily of solute carriers | SLC22A8 | Solute carrier family 22 member 8 | Q8TCC7 | CHEMBL1641348 |
| SLC superfamily of solute carriers | SLC22A6 | Solute carrier family 22 member 6 | Q4U2R8 | CHEMBL1641347 |
| Small molecule receptor (family A GPCR) | FFAR1 | Free fatty acid receptor 1 | O14842 | CHEMBL4422 |
| Toll-like and Il-1 receptors | TLR2 | Toll-like receptor 2 | O60603 | CHEMBL4163 |
| Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
| Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
| Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | FABP3 | Fatty acid binding protein muscle | P05413 | CHEMBL3344 |
| Unclassified | FABP5 | Fatty acid binding protein epidermal | Q01469 | CHEMBL3674 |
| Unclassified | FABP2 | Fatty acid binding protein intestinal | P12104 | CHEMBL4879 |
| Unclassified | FABP4 | Fatty acid binding protein adipocyte | P15090 | CHEMBL2083 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 3.280E-13 | 7.142E-10 | CA1, CA12, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9, MMP1, MMP2, MMP9, PPARA, PPARD, PTPN1, TP53 |
| BP | GO:0008152; metabolic process | GO:0019433; triglyceride catabolic process | 2.362E-07 | 2.143E-04 | FABP2, FABP3, FABP4, FABP5 |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 1.665E-27 | 3.625E-23 | CA1, CA12, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
| CC | GO:0016020; membrane | GO:0016323; basolateral plasma membrane | 2.892E-06 | 1.536E-03 | CA2, CA4, CA9, SLC22A6, SLC22A8, TSHR |
| BP | GO:0050896; response to stimulus | GO:0010038; response to metal ion | 5.153E-06 | 2.387E-03 | ALOX15, CA2, FABP4, HIF1A, MAPK1, MMP9, TP53 |
| BP | GO:0009987; cellular process | GO:0050714; positive regulation of protein secretion | 1.106E-05 | 4.279E-03 | ACHE, CASP1, FFAR1, HIF1A, PPARD, TLR2 |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 1.383E-05 | 5.103E-03 | CA2, CA7 |
| BP | GO:0050896; response to stimulus | GO:0033993; response to lipid | 1.995E-05 | 6.684E-03 | CA2, CA9, CASP1, FABP3, FFAR1, NFKB1, PPARD, TLR2, TP53 |
| BP | GO:0050896; response to stimulus | GO:0014070; response to organic cyclic compound | 2.107E-05 | 6.911E-03 | CA2, CA9, CASP1, CASP7, MAPK1, NFKB1, SLC22A6, TLR2, TP53 |
| BP | GO:0008152; metabolic process | GO:0009299; mRNA transcription | 2.126E-05 | 6.911E-03 | HIF1A, PPARD, TP53 |
| BP | GO:0050896; response to stimulus | GO:0042060; wound healing | 2.329E-05 | 7.407E-03 | ALOX15, PPARA, PPARD, TP53 |
| BP | GO:0050896; response to stimulus | GO:0042493; response to drug | 2.347E-05 | 7.407E-03 | CA3, CA9, CASP1, FABP3, MAPK1, NFKB1, SLC22A6, TLR2, TP53 |
| BP | GO:0008152; metabolic process | GO:0032963; collagen metabolic process | 2.845E-05 | 8.604E-03 | HIF1A, MMP1, MMP2, MMP9 |
| BP | GO:0032501; multicellular organismal process | GO:0001816; cytokine production | 3.132E-05 | 9.217E-03 | CASP1, FABP4, HIF1A, TLR2 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 8.963E-21 | 9.758E-17 | CA1, CA12, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 1.809E-19 | 9.848E-16 | CA1, CA12, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
| MF | GO:0003824; catalytic activity | GO:0004064; arylesterase activity | 6.885E-05 | 1.640E-02 | CA1, CA2 |
| MF | GO:0005488; binding | GO:0097371; MDM2/MDM4 family protein binding | 9.626E-05 | 2.117E-02 | PPARA, TP53 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 1.027E-26 | 1.540E-24 | CA12, CA1, CA3, CA5B, CA2, CA5A, CA4, CA7, CA6, CA9, CA14 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa03320 | PPAR signaling pathway | 1.043E-10 | 7.824E-09 | FABP2, FABP3, FABP4, FABP5, MMP1, PPARA, PPARD |
| 09160 Human Diseases | 09161 Cancers | hsa05219 | Bladder cancer | 2.263E-08 | 1.131E-06 | MMP1, MMP2, MAPK1, MMP9, TP53 |
| 09160 Human Diseases | 09161 Cancers | hsa05200 | Pathways in cancer | 1.469E-06 | 5.509E-05 | MMP1, MMP2, MAPK1, HIF1A, TP53, MMP9, NFKB1, PPARD |
| 09160 Human Diseases | 09161 Cancers | hsa05205 | Proteoglycans in cancer | 3.929E-06 | 1.179E-04 | MMP2, MAPK1, TP53, HIF1A, MMP9, TLR2 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05134 | Legionellosis | 5.300E-06 | 1.325E-04 | CASP7, CASP1, NFKB1, TLR2 |
| 09140 Cellular Processes | 09143 Cell growth and death | hsa04210 | Apoptosis | 1.081E-05 | 2.315E-04 | CASP7, LMNA, MAPK1, TP53, NFKB1 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05161 | Hepatitis B | 1.324E-05 | 2.483E-04 | MAPK1, TP53, MMP9, NFKB1, TLR2 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05133 | Pertussis | 1.832E-05 | 3.054E-04 | CASP7, CASP1, MAPK1, NFKB1 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04668 | TNF signaling pathway | 8.253E-05 | 1.125E-03 | CASP7, MAPK1, MMP9, NFKB1 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05160 | Hepatitis C | 1.720E-04 | 1.984E-03 | MAPK1, PPARA, TP53, NFKB1 |
| 09160 Human Diseases | 09161 Cancers | hsa05221 | Acute myeloid leukemia | 2.328E-04 | 2.328E-03 | MAPK1, NFKB1, PPARD |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00983 | Drug metabolism - other enzymes | 1.228E-04 | 1.534E-03 | CYP2A6, CYP3A4, XDH |
| 09160 Human Diseases | 09161 Cancers | hsa05212 | Pancreatic cancer | 3.594E-04 | 3.131E-03 | MAPK1, TP53, NFKB1 |
| 09150 Organismal Systems | 09151 Immune system | hsa04621 | NOD-like receptor signaling pathway | 2.328E-04 | 2.328E-03 | CASP1, MAPK1, NFKB1 |
| 09100 Metabolism | 09108 Metabolism of cofactors and vitamins | hsa00830 | Retinol metabolism | 3.436E-04 | 3.131E-03 | CYP2A6, ALDH1A1, CYP3A4 |
| 09160 Human Diseases | 09161 Cancers | hsa05230 | Central carbon metabolism in cancer | 3.757E-04 | 3.131E-03 | MAPK1, TP53, HIF1A |
| 09160 Human Diseases | 09161 Cancers | hsa05220 | Chronic myeloid leukemia | 4.835E-04 | 3.454E-03 | MAPK1, TP53, NFKB1 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04024 | cAMP signaling pathway | 7.919E-04 | 5.164E-03 | MAPK1, PPARA, NFKB1, TSHR |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05140 | Leishmaniasis | 4.835E-04 | 3.454E-03 | MAPK1, NFKB1, TLR2 |
| 09160 Human Diseases | 09161 Cancers | hsa05215 | Prostate cancer | 8.625E-04 | 5.391E-03 | MAPK1, TP53, NFKB1 |
| 09150 Organismal Systems | 09154 Digestive system | hsa04976 | Bile secretion | 4.456E-04 | 3.454E-03 | CA2, SLC22A8, CYP3A4 |
| 09160 Human Diseases | 09166 Endocrine and metabolic diseases | hsa04933 | AGE-RAGE signaling pathway in diabetic complications | 1.244E-03 | 6.910E-03 | MMP2, MAPK1, NFKB1 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04915 | Estrogen signaling pathway | 1.174E-03 | 6.773E-03 | MMP2, MAPK1, MMP9 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05132 | Salmonella infection | 7.807E-04 | 5.164E-03 | CASP1, MAPK1, NFKB1 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04066 | HIF-1 signaling pathway | 1.316E-03 | 6.999E-03 | MAPK1, HIF1A, NFKB1 |
| 09150 Organismal Systems | 09151 Immune system | hsa04620 | Toll-like receptor signaling pathway | 1.429E-03 | 7.147E-03 | MAPK1, NFKB1, TLR2 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05142 | Chagas disease (American trypanosomiasis) | 1.353E-03 | 6.999E-03 | MAPK1, NFKB1, TLR2 |
| 09160 Human Diseases | 09166 Endocrine and metabolic diseases | hsa04931 | Insulin resistance | 1.549E-03 | 7.494E-03 | PTPN1, PPARA, NFKB1 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05145 | Toxoplasmosis | 1.943E-03 | 8.266E-03 | MAPK1, NFKB1, TLR2 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04919 | Thyroid hormone signaling pathway | 1.943E-03 | 8.266E-03 | MAPK1, TP53, HIF1A |
| 09150 Organismal Systems | 09156 Nervous system | hsa04722 | Neurotrophin signaling pathway | 2.039E-03 | 8.266E-03 | MAPK1, TP53, NFKB1 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04071 | Sphingolipid signaling pathway | 2.039E-03 | 8.266E-03 | MAPK1, TP53, NFKB1 |
| 09160 Human Diseases | 09161 Cancers | hsa05216 | Thyroid cancer | 1.686E-03 | 7.664E-03 | MAPK1, TP53 |
| 09150 Organismal Systems | 09155 Excretory system | hsa04964 | Proximal tubule bicarbonate reclamation | 1.059E-03 | 6.355E-03 | CA2, CA4 |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00591 | Linoleic acid metabolism | 1.686E-03 | 7.664E-03 | ALOX15, CYP3A4 |
| 09100 Metabolism | 09110 Biosynthesis of other secondary metabolites | hsa00232 | Caffeine metabolism | 4.288E-05 | 6.432E-04 | CYP2A6, XDH |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | TP53; |
| H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | MMP2; |
| C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | MMP2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | NFKB1; |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | TP53; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | MMP1; |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | MMP9; TP53; MMP2; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | MMP1; |
| C00-D49: Neoplasms | Cancer | C00-C96 | NFKB1; MMP9; TP53; MMP2; |
| K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | MMP9; |
| I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53; |
| C00-D49: Neoplasms | Renal cell carcinoma | NA | MMP2; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53; |
| C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | TP53; |
| C00-D49: Neoplasms | Lung cancer | C33-C34 | MMP2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic nephropathy | E11.21 | MMP1; |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | TP53; |
| I00-I99: Diseases of the circulatory system | Stroke | I61-I63, I80-I82 | MMP9; |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | MMP9; TP53; |
| C00-D49: Neoplasms | Non-small-cell lung cancer | NA | MMP2; |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR; |
| C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR; |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR; |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | MMP2; |
| C00-D49: Neoplasms | Ovarian cancer | C56 | MMP2; |
>> Profiles of ingredients and activity landscape
>> Targets derived from weak experimental activities
